Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1076 participants.

Also called NCT05968430

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,076 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05968430
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05968430. Non-randomized; no masking; primary purpose treatment. Start 2023-07-14 (actual); primary completion 2025-12-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
Condition
Hypertension
Intervention (Drug)
lorundrostat
Intervention (Drug)
Placebo
Lead sponsor
Mineralys Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct05968430
Content hash
01fbdc88ec17842882d10b15ffe1c77f8bf79d3809803220bb31abd25bf86f42